MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.76
-0.65
-6.91%
Closed 18:15 04/19 EDT
OPEN
9.41
PREV CLOSE
9.41
HIGH
9.50
LOW
8.67
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
14.39
52 WEEK LOW
7.80
MARKET CAP
437.33M
P/E (TTM)
-3.3500
1D
5D
1M
3M
1Y
5Y
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Flexion Therapeutics (FLXN) and Inovio Pharmaceuticals (INO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Flexion Therapeutics (FLXN) and Inovio Pharmaceuticals (INO). Flexion
SmarterAnalyst · 1d ago
Thinking about buying stock in Grupo Televisa, Phunware, Immunitybio, Flexion Therapeutics, or Amicus Therapeutics?
NEW YORK, April 14, 2021 /PRNewswire via COMTEX/ -- NEW YORK, April 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TV,...
PR Newswire - PRF · 5d ago
DJ Flexion Therapeutics Price Target Cut to $17.00/Share From $18.00 by Credit Suisse
Dow Jones · 5d ago
DJ Flexion Therapeutics Is Maintained at Outperform by Credit Suisse
Dow Jones · 5d ago
Flexion Therapeutics (FLXN) Receives a Buy from Credit Suisse
Credit Suisse analyst Martin Auster maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $17.00. The company's shares
SmarterAnalyst · 5d ago
Credit Suisse Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $17
Credit Suisse analyst Martin Auster maintains Flexion Therapeutics (NASDAQ:FLXN) with a Outperform and lowers the price target from $18 to $17.
Benzinga · 5d ago
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 5d ago
DJ Flexion Therapeutics Price Target Cut to $16.00/Share From $18.00 by Raymond James
Dow Jones · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLXN. Analyze the recent business situations of Flexion through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLXN stock price target is 19.77 with a high estimate of 35.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 210
Institutional Holdings: 53.81M
% Owned: 107.78%
Shares Outstanding: 49.92M
TypeInstitutionsShares
Increased
44
2.82M
New
26
1.21M
Decreased
39
2.20M
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.60%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Mahaffy
President/Chief Executive Officer/Director
Michael Clayman
Chief Financial Officer
David Arkowitz
General Counsel/Secretary
Mark Levine
Other
Scott Kelley
Other
Melissa Layman
Other
Kerry Wentworth
Other
Christina Willwerth
Director
Elizabeth Kwo
Independent Director
Scott Canute
Independent Director
Samuel Colella
Independent Director
Heath Lukatch
Independent Director
Sandesh Mahatme
Independent Director
Ann Merrifield
Independent Director
C. Ann Merrifield
Independent Director
Alan Milinazzo
Independent Director
Mark Stejbach
No Data
  • All
  • Financials
  • Insiders
More
About FLXN
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Webull offers kinds of Flexion Therapeutics Inc stock information, including NASDAQ:FLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLXN stock methods without spending real money on the virtual paper trading platform.